

# REFERENCES

- Adams DH and ARL Loyd. Chemokines: Leucocyte recruitment and activation cytokine. *Lancet* 1997; 349: 490.
- Adams DH and Shaw S. Leucocyte endothelial interaction and regulation of leucocyte migration. *Lancet*, 1994; 343: 831.
- Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *HEPATOLOGY* 2001;33:1358-1364.
- Albanis E, Friedman SL. Diagnosis of hepatic fibrosis in patients with chronic hepatitis C. *Clin liver Dis* 2006; 10: 821-833.
- Albanis E, Friedman SL. Non-invasive markers of hepatic fibrosis. *Clinical perspectives in Gastroenterology* 2002; 5(3): 182-187
  
- Albercht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD Jayaram V, Eckersley R, Urbank A, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. *Lancet* 1999; 353: 1579-1583.
- Alberti A, Chemello L, Cavulatto D, Tagger A, Dal Canton A. Antibodies to hepatitis C virus and liver disease in volunteers blood donors *Hepatology* 2002.
  
- Albert Zlotnik\*‡ and Osamu Yoshie†‡ Chemokines: A New Classification System and Their Role in Immunity *Immunity*, Vol. 12, 121–127, February, 2000 : 121-127

- Al-Faleh FZ, Ramia S, Arif M, Ayoola EA, al-Rashed RS, Al-Jeffry M, Hossain A, et al. Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: a community-based study. *Ann Trop Med parasitol.* 1995; 89: 431-7.
- Al-Sherbiny M, Osman A, Mohamed N, Abdel-Wahab SF, Mikhail N, Stoszek S, Strickland GT, et al. Exposure to hepatitis C virus induce cellular immune responses without detectable viremia or seroconversion. *Am. J. Trop. Med. Hyg.* 2005; 73: 44-9.
- Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA et al. The prevalence of hepatitis C virus infection in the united states 1988 through 1994. *N. Engl. J Med.* 1999; 341: 556-62.
- Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigby MO, Di Bis Geglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. *Ann Intern Med.* 2004; 141: 715-717.
- Amin J, Gidding H, Gilbert G, Backhouse J, Kaldor J, Dore G, Burgess H. Hepatitis C prevalence a nationwide serosurvey. *Commun. Dis. Intell.* 2004; 28(4): 517-21.
- Andriulli A, Festa V, Leandro G, Rizzetto M, AIGO members. Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis Viral infection. *Dig Dis Sci* 2001; 46: 1409-1415.
- Angello V, Abel G, Elfahal M, Knight GB, Zhang GX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc Natl Acad Sci USA* 1999; 96: 12766-71.

- Apichartpiyakul C, Apichartpiyakul N, Urwijitaroon Y, Gray J, Natpratan C, Katayama Y, Fujii M, Hotta H. Seroprevalence and subtype distribution of hepatitis C virus among blood donors and intravenous drug users in northern northeastern Thailand. *Jpn J Infect. Dis.* 1999; 52: 121-3.
- Apolinario A, Majano PL, Alvarez-Perez E, Saez A, Lozano C, Vargas J, Garcia-Monzon C. Increased expression of T-cell chemokines and their receptors in chronic hepatitis C: relationship with histological activity of liver disease. *Am. J. Gastroenterol* 2002; 97: 2861-2870.
- Arafa N, El-Hoseiny M, Rekecewicz C, Bakr I, Et-Kafrawy S, El Daly M, Aoun S, et al. Changing pattern of hepatitis C virus spread in rural areas of Egypt. *J. Hepatol* 2005; 43(3): 418-24.
- Asselah T, Rubbia-Brandt L, Marcellin P and Negro F. Steatosis in chronic hepatitis C: Why does it really matter? *Gut* 2006; 55: 123-130.
- Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. *Am J Gastroenterol* 2000; 95: 1545-1550.
- Atter MJ, Prevention of spread of hepatitis C. *Hepatology* 2002; 56(Suppl): S93-98.
- Aurora, R., Donlin, M.J., Cannon, N.A., and Tavis, J.E., for the Virahep-C Study Group. 2009. Genomewide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. *J. Clin. Invest.* 119:225–236

- Bacon K, Baggiolini M, Broxmeyer H, et al. Chemokine/chemokine receptor nomenclature. *J Interferon Cytokine Res* 2002;22:1067-8.
- .Baggiolini M. Chemokines and leukocyte traffic. *Nature* 1998; 392: 565.
- Baggiolini M. Chemokines in pathology and medicine. *J Intern Med* 2001;250: 91-104.
- Barna TK, Ozsvar Z, Szendrenyi V, Gal G. Hepatitis C virus antibody in serum of blood donors. *Orvosi Hetilap* 1996; 137: 507-11.
- Bartenschlager R, Lohmann V. Replication of hepatitis C virus. *Journal of General virology* 2000; 81: 1631-48.
- Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, Thimme R, et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. *Blood* 2005; 105: 3605-14.
- Bassily S, Hyams KC, Fouad RA, Samaan MD, Hibbs RG. A high risk of hepatitis C infection among Egyptian blood donors: the role of parental drug abuse. *Am J Trop Med. Hyg.* 1995; 52(6): 503-5.
- Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. *Nature* 1997; 385:640-4.
- Beardsley AM, La Brooy JT, Rozen L, Gowans EJ. A comparison of hepatitis C virus (HCV)-RNA and antibody as markers of infection and predictor of infectivity. *Aust N Z J Med* 1994; 24: 182-187.
- Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry* 1961; 4: 561-571.

- Bedossa P. Interobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Metavia Cooperative study group. *Hepatology*. 1994; 20: 15-20
- Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *HEpatology* 1996; 24: 289-293.
- Beld M, Penning M, McMorrow M, Gorgels J, Van den Hoek A, Goudsmit J. Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels. *J Clin Microbiol* 1998; 36: 872-7.
- Bellentani S, Tiribelli C. The spectrum of liver disease in general population: Lesson from the Dionysos study. *J. Hepatol.* 2001; 35: 531-537.
- Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. *Hepatology* 2003; 38: 4-13.
- Devalaraja RM, Nanney LB, Du J, et al Delayed wound healing in CXCR2 knockout mice. *J Invest Dermatol* 2000;115:234- 44
- Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. *J Virol.* 2001;75: 7059-7066.
- Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. *Semin Thromb Hemost* 2004;30:379-85.
- Boisvert J, Kunkel EJ, Campbell JJ, Keeffe EB, Butcher EC, Greenberg HB. Liver-infiltrating lymphocytes in end-stage hepatitis C virus:

subsets, activation status, and chemokine receptor phenotypes. *J Hepatol.* 2003;38: 67-75.

- Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 helper cells (Th1S) and Th2S J. Exp. Med. 1998; 187: 129-134.
- Burits CH, Ashwood ER (eds) Teitz fundamentals of clinical chemistry. 4<sup>th</sup> Ed. Philadelphia: W.B. Saunders Company 1996.
- Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. *Cell* 1991; 67: 1033.
- Butcher EC and Picker J. Lymphocyte homing and homeostasis *Science* 1996; 272: 60.
- Campbell JJSX, Qin KB, Bacon CR, Mackay and EC Butcher. Biology of chemokine and classical chemoattractant receptors- differential requirements for adhesion-Triggering versus chemotactic responses in lymphoid-cells. *J. Cell Biol* 1996; 134: 255.
- Castera L, Foucher J, Bertet J, Couzigou P, and De Ledinghem V. Fibroscan and fibrotest to assess liver fibrosis in HCV with normal aminotransferases. *Hepatology* 2006; 43(2): 373-374.
- Casato M, Lilli D, Granata M, Conti V, Del Giudice G, Rivanera D. Occult hepatitis C virus infection in type II mixed cryoglobulinemia. *Journal of viral hepatitis*, 2003; 10: 455-459.
- CATHERINE J. E-SMITH, JULIE R., DAVID M., AMOLAK B, CLAUDIA S., AND ELIZABETH E. , Interleukin-10 Promoter Polymorphism Predicts Initial Response of Chronic Hepatitis C to Interferon Alfa *HEPATOLOGY* Vol. 30, No. 2, 1999 526:530

- Chen J, Vistica BP, Takase H, Ham DI, Fariss RN, Wowrousek EF, Chan CC, De Martino JA, Farber JM, Gery I. A unique pattern of up-and down-regulation of chemokine receptor CXCR3 on inflammatory-inducing Th1 cells. *Eur. J. Immunol.* 2004; 34: 2885-94.
- Cianico A, Manzini P, Castagno F, D'Antico S, Reynaudo P, Coucourde L, Ciccone G, et al. Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus. *Ann Intern Med.* 2005; 142(11): 903-909.
- Clark-Lewis I, Maltoli I, Gong JH, Loetscher P. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. *J Biol. Chem.* 2003; 278: 289-295.
- Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Terpo C. Sensitivity and specificity of third-generation hepatitis C antibody detection assays: An analysis of the Literature. *J viral Hepat.* 2001; 8(2): 87-95.
- Conry-Cantilena C, Van Raden M, Gible J, Melpolder J, Shakil AO, Viladoni L et al. Routes of infection, viremia and liver disease in blood donors found to have hepatitis C virus infection. *N Eng J Med* 1996; 334: 1691-1696.
- Cox AL, Netski DM, Mosbrugger T, Sherman SG, Strathdee S, Ompad D, Vlahov D, et al. prospective evaluation of community acquired

acute-phase hepatitis C virus infection. *Clin Infect Dis* 2005; 40(7): 951-958.

- Craig Murdoch and Adam Finn , *BLOOD*, 15 MAY 2000 x VOLUME 95, NUMBER 10 : 3032- 3043
- Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, Naoumov NV. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. *Gut* 1999; 44: 424-9.
- Cyster JG. Chemorepulsion and thymocyte emigration. *J Clin. Invest.* 2002; 109: 1011-1012.
- Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. *Annu Rev Immunol* 2005;23:127-59.
- Dacie JVV, Lewis SM. Investigation of a bleeding tendency. In: *Practical hematology*, 8<sup>th</sup> ed. Edinburgh: Churchill Livingstone: 1995; 317-35.
- Dal Molin G, D'Agaro P, Ansaldi F, Ciana G, Fertz C, Alberico S, Campello C. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. *J. Med. Virol.* 2002; 67(2): 137-142.
- Damen M, Cuypers HT, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH, Niesters HG, et al. International Collaborative study on the second EUROHEP HCV-RNA reference panel. *J Virol Methods* 1996; 58: 175-185.
- Darwish MA, Raouf TA, Rushdy P, Constantine NT, Rao MR, Edelman R. Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. *Am. J. Trop Med Hyg.* 1993; 49(4): 440-7.

- Darwish NM, Abbas MO, Abdel Fattah FM, Darwish MA. Hepatitis C virus infection in blood donors in Egypt J. Egypt Public Health Assoc. 1992; 67(3-4): 223-36.
- David Buttera, Svetlana Marukian, Amy E. Iwamaye, Edgardo Hembrador, Thomas J. Chambers, Adrian M. Di Bisceglie, Edgar D. Charles et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. J Blood 2005 August 15; 106 (4):1175-1182.
- Davis, G. L. (2002). Monitoring of viral levels during therapy of hepatitis C. Hepatology 36, Suppl. 1, S145–51.
- . Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C. et al. (1998). Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. NEJ of Medicine 339, 1493–9.
- . Deleersnyder V, Pillez A, Wychowski C, Blight K, Xu J, Hahn YS, Rice CM, et al. Formation of native hepatitis C virus glycoprotein complexes. Journal of virology 1997; 71: 697-704.
- Del Prete G, Maggi E, Romagnani S. Human Th1 and Th2 cells: Functional properties, mechanisms of regulation and role in disease. Lab Invest 1994; 70: 299-306.
- Devalaraja RM, Nanney LB Du et al. Delayed wound healing in CXCR2 knockout mice. J Invest. Dermatol. 2000, 115 :234-44.
- Diedrich G. How does hepatitis C virus enter cells? FEBS Journal 2006; 3871-85.
- Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, et al. Possible mechanism involving T-

- lymphocyte response to NS protein 3 in viral clearance in acute hepatitis C virus infection. *Lancet* 1999; 346: 1006-7.
- Dienstug JL. The role of liver biopsy in chronic hepatitis C. 2002; 36: S152-160.
  - Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D and Pape GR. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. 1999; 346: 1006.
  - Dries V, Both IV, Müller M, Gerken G, Schirmacher P, Odenthal M, Bartenschlager R, et al. Detection of hepatitis C virus in paraffin Embedded liver Biopsies of patients Negative for viral RNA in serum *Hepatology* 1999; 29: 223-229.
  - Dubois F, Desenclos JC, Mariotte N, Goudean A. Hepatitis C in a French population based survey. 1994: Seroprevalence frequency of viremia, genotype distribution and risk factors, the collaborative study group. *Hepatology* 1997; 25: 1490-1496.
  - Dumoulin FL, Bach A, Leifeld L, EL-Bakri M, Fischer HP, Tsauerbruch and Spengler U. Semiquantitative analysis of intrahepatic expression of Th1-associated cytokines. *Hepatology* 1997; 24: 759.
  - El-Shamy, A., et al. 2007. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pretreatment
  - Fanning L. Natural fluctuations of hepatitis C viral load in a homogenous patients population: a prospective study. *Hepatology* 2000; 31: 225-29.

- Farber JM. Mig & IP-10: CXC chemokines that target lymphocytes. *J. Leuko. Biol.* 1997; 61: 246-257.
- Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M et al. Prevention of hepatitis C virus infections in chimpanzees after antibody-mediated in vitro neutralization. *Proc Natl Acad Sci USA* 1994; 91: 7792-6.
- Farid A, Al-Sherbiny M, Osman A, Mohamed N, Lee DH, Prince AM, Strickland GT, et al. Schistosoma infection inhibit cellular immune responses to core HCV peptides. *Parasite Immunol.* 2005; 27(5): 189-196.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347(13): 975-982.
- Fattovich G, Givstina G, Degos F, Tremolada F, Diodati G, Almasio L et al. Morbidity and mortality in compensated cirrhosis type C a retrospective follow-up study of 384 patients. *Gastroenterology* 1997; 112; 463-472.
- Favre D, Berthillon P, Trepo C. Removal of cell-bound lipoproteins: a crucial step in the efficient infection of liver cells with hepatitis C virus in vitro. *CR Acad Sci III* 2001; 324: 1141-8
- Ferenci P, Fried MW, Smith CI, Marinos G, Goncales FL, Jr et al. Predicting sustained virological response in chronic hepatitis C patients treated with peginterferon alfa2-a (40 KD), ribavirin. *J Hepatology* 2005; 43: 425-433.

- Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T, Schianchi C, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. *HEPATOLOGY* 1994;19:286-295
- Fong AM, Robinson LA, Steeber DA, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. *J Exp Med* 1998;188:1413-9.
- Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, et al. Hepatitis activity index is a key factor in determining the natural history of hepatitis C. *Hum Pathol* 2001; 32: 904-909.
- Fontana RJ, Lok AS. Non invasive monitoring of patients with chronic hepatitis C. *Hepatology* 2002; 36: 5.
- Foy E, Lik, Wang C, Sumpter RJ, Ikeda M, Lemon SM, Gale MJ. Regulation of interferon regulatory factor-3 by hepatitis C virus serine protease. *Science* 2003; 300: 1145-8.
- Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000; 355: 887-91.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Mrinos G, Goncoles FL, JT et al. Peginterferon alfa2-a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975-982.

- Garton KJ, Gough PJ, Blobel CP, et al. Tumor necrosis factor- $\alpha$ -converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). *J Biol Chem* 2001;276:37993-8001.
- Gebo KA, Herlong HF, Torbenson MS, Jenkes MW, Chander G, Ghanem KG, El-Kamary SS, et al. A role of liver biopsy in management of chronic hepatitis C: a systematic review. *Hepatology* 2002; 36: S161-172.
- Gerszten RE, Garcia-Zepeda EA, Lim Y-C, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. *Nature* 1999; 398:718-23.
- Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, Butler K. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. *Lancet*. 2000; 356 (9233): 904-7.
- Glynn SA, Wright DJ, Kleinman SH, Hirschorn D, Tu Y, Heldebrant C, Smith R et al. Dynamics of viremia in early hepatitis C virus infection. *Transfusion* 2005; 45(6): 994-1002.
- Goedert JJ, Chen BE, Preiss L, Aledort LM, Rosenberg PS. Reconstruction of the hepatitis C virus epidemic in US hemophilia population 1940-1990. *Am J Epidemiol* 2007; 165: 1443-1453.
- Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. *Semin liver Dis* 1995; 15: 70-81.
- Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. *Hepatology* 1998; 28: 1702-6.

- Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht JK. The significance of baseline serum alanine amino transferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. *Hepatology* 2000; 32: 400-404.
- Halfon P, Bourliere M, Halimi G, Khiri H, Bertezene P, Portal I, Botta-Fridlund D et al. Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: branched DNA and Amplicor Monitor. *J Clin Microbiol* 1998; 36: 2073-5.
- Handel TM, Domaille PJ. Heteronuclear (<sup>1</sup>H, <sup>13</sup>C, <sup>15</sup>N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. *Biochemistry* 1996;35:6569-84. Gerard C, Rollins BJ. Chemokines and disease. *Nat Immunol* 2001;2:108-15.
- Harvey CE, Post JJ, Palladinetti P, Freeman AJ, French RA, Kumar RK, Marinos G, Lloyd AR. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. *J. Leukoc. Biol.* 2003; 74: 360-369.
- Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction: rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. *J Biol Chem* 1999;274:10053-8.
- Heathcote, E. J., Shiffman, M. L., Cooksley, W. G., Dusheiko, G. M., Lee, S. S., Balart, L. et al. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. *New England Journal of Medicine* 343, 1673–80.

- Hechtman DH, Cybulsky MI, Fuchs HJ, Baker JB, Gimbrone MA Jr. Intravascular IL-8 inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. *J Immunol.* 1991; 147: 883-892.
- Helbig KJ, George J, Beard MR. A novel I-TAC promoter polymorphism variant is functional in the presence of replicating HCV in vitro. *J. Clin. Virol.* 2005; 32: 137-143.
- Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McCall SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. *Hepatology* 2004; 39: 1220-1229.
- Henderson DK. Managing Occupational Risks for Hepatitis C transmission in the Health care setting. *Clinical Microbiology Reviews* 2003; 16(3): 546-568.
- Higashi Y, Mizushima A, Motsumoto H. Introduction to abdominal ultrasonography 1<sup>st</sup> ed. Berlin, Heidelberg. New York: Springer-verlag 1991; 76-83.
- Hillemanns P, Dannecker C, Kimmig R, Hasbargen U. Obstetric risks and vertical transmission of hepatitis C virus infection in pregnancy. *Acta obstet Gynecol. Scand.* 2000; 79(7): 543-547.
- Houghton M. Hepatitis C viruses. In: Fields BN, Knipe DM, Howley PM, eds *Fields virology*, 3<sup>rd</sup> ed. Philadelphia, Lippincott-Raven, 1996: 1035-58.
- Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates

significantly with body mass index and steatosis. HEPATOLOGY

1999;29:1215-1219.

- Huber KR, Sebesta C, Bauer K. Detection of common hepatitis C virus subtypes with a third-generation enzyme immunoassay. Hepatology 1996; 24: 471-473.
- Huo Y, Weber C, Forlow SB, et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium J Clin Invest 2001;108:1307-14.
- Ilako FM, McLigeyo SO, Riyat MS, Lule GN, Okoth FA, Kaptich D. The prevalence of hepatitis C virus antibodies in renal patients, blood donors and patients with chronic liver disease in Kenya. East Afr. Med. J 1995; 72: 362-4.
- Ishak K, Baptista A, Bainchi L, Callea F, DeGroote J, Gudat F, Denk H, et al. Histologic grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
- Jacobson IM, Brown RS Jr, Freilich B, Afdhol N, Kwo PY, Santoro J, et al. Peginterferon alfa 2-b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-981.
- Kakimi K, Lane TE, Wieland S, et al. Blocking chemokine receptor responsive to  $\gamma$ -2 interferon (IFN)- $\gamma$  inducible protein and monokine induced by IFN-  $\gamma$  activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T-lymphocytes. J Exp Med. 2001; 194: 1755-1766.

- Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. *J. Hepatol.* 2000; 32: 172-4.
- Kamal SM, Turner B, Koziel MJ, Afdhal NH. YKL-40 and PIII NP correlate with the progression of fibrosis in chronic hepatitis C (Abstract). *Gastroenterology* 2001; 120: 189SA.
- Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schiroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. *J Exp Med.* 1992(176): 587-592.
- Karpus WJ, Lukace NW, Kennedy KJ, Smith WS, Hurst SD, Barrett TA. Differential CC chemokine-induced enhancement of T-helper cell cytokine production. *J Immunol.* 1997; 158: 4129-4136.
- Kelner GS, Kennedy J, Bacon KB, et al Lymphotactin: a cytokine that represents a new class of chemokine. *Science* 1994; 266:1395-9.
- Kleiner DE. The liver biopsy in chronic hepatitis C: A view from the other side of the microscope. *Semin liver Dis* 2005; 25: 52-64.
- Klenerman P, Semmo N, Cellular immune responses against persistent hepatitis C virus. Gone but not forgotten. *Gut* 2006; 55: 914-916.
- Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kierman TW, et al. Formulation and application of a numeral scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1981; 1: 431-435.
- Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawoda N, Habu D, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy, a multicenter, retrospective cohort study of 1124 patients. *Liver Int.* 2007; 27: 186-191.

- Lagging M, Romero A, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. *HEPATOLOGY* 2006;44:1617-1625.
- Larsen CG, Anderson AO, Appella E, Oppenheim JJ and Mastushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T-lymphocytes *Science* 1989; 243: 1464.
- Lasarte JJ, Garcia-Granero M, Lopez A, Casares N, Garcia N, Civeira MP, Borrás-Cuesta F, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. *HEPATOLOGY* 1998;28:815-822
- Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med.* 2001;345: 41-52.
- Lee S, Macquillan GC, Keane NM, Flexman J, Jeffrey GP, French MA, et al. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. *Immunol Cell Biol* 2002;80: 391-397.
- Lerat H, Hollinger FB. Hepatitis C virus occult infection or occult HCV RNA detection. *Journal of infectious Diseases* 2004; 189: 3-6.
- Liu X, Das AM, Seideman J, Griswold D, Afuh CN, Kobayashi T, et al. The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6. *Am J Reprod Cell Mol Biol* 2007; 37: 121-128.
- Loetscher M, Gerber B, Loetscher P, Jones AS, Piali L, Clark-Lewis I, Baggiolini M and Bernard M. Chemokine receptor specific for IP-10 and mig: structure, function and expression in activated T-lymphocytes *J. Exp. Med* 1996; 184(3): 963-969.

- Loetscher P, Pellegrino A, Gong JH, et al. The ligands of CXC chemokine receptor 3, 1-TAC, Mig, and IP10 are natural antagonists for CCR3. *J Biol Chem.* 2001; 276: 2986-2991.
- Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C and Dayer JM. CCRs is characteristic of Th1 lymphocytes. *Nature* 1998; 391: 344.
- Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 1999b; 285: 110-13.
- Lusinskas F, Kiely J, Ding H, et al. In vitro inhibitory effect of IL-8 and other chemoattractants on neutrophil-endothelial adhesive interactions. *J Immunol.* 1992; 149: 2163-2171.
- Luster AD. Chemokines — chemotactic cytokines that mediate inflammation. *NEJ Med* 1998;338:436-45.
- Luster AD, Greenberg SM, Leder P. IP-10 chemokine binds to a specific cell surface heparin sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. *J. Exp. Med.* 1995; 182(1): 219-231.
- Luster AD, Jhanwar SC, Changanti R.S.K, Kersey JH and Ravetch JV. Interferon-inducible gene maps to a chromosomal band associated with a (4;11) Translocation in acute leukemia cells. *J. Proc Natl. Acad. Sci USA* 1987; 24: 2868-2871.
- Mackay CR. Chemokines: immunology's high impact factors-*Nat. Immunol.* 2001; 2: 95-101.
- Mackay CR. Chemokine receptors and T-cell chemotaxis. *J Exp. Med* 1996; 184: 799.

- Maclene E, Young DS. Automation in clinical laboratory. In: Burtis CA, Ashwood ER (eds). Teitz textbook of clinical chemistry 2<sup>nd</sup> (ed) Philadelphia: WB. Saunders company 1994; 313-373.
- Manns MP, Mc Hutchison J, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa2-b plus ribavirin compared with interferon alfa 2-b plus ribaririn for initial treatment of chronic hepatitis C, a randomized trial Lancet 2001; 358: 958-965.
  - Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999;20:254-7.
  - Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A 1998;95:9448-53.
  - Marc G Ghay, Doris B. Strader, David L. Thomas and Leonard B. Seff. Diagnosis, Management and treatment of hepatitis C: An update Hepatology 2009; 49(4): 1343.
  - Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV-RNA in patients with chronic hepatitis C and sustained response to IFN- $\alpha$  and ribavirin. An Intern Med. 1997; 127(10): 875-8
  - Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: 47-56.
- Marcellin P. Hepatitis C: The clinical spectrum of the disease. Journal of Hepatology 1999; 3: 9-16.
- Martins-Green M, Hanafusa H. The 9E3/CEF4 gene and its product the chicken chemotactic and angiogenic factor (cCAF): potential roles in

wound healing and tumor development. *Cytokine Growth Factor Rev* 1997;8:221-32.

- Martinot-Peignoux, M., Boyer, N., Pouteau, M., Castelnau, C., Giuily, N., Duchatelle, V. et al. (1998). Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. *Journal of Hepatology* 29, 214–23.
- Marx G Ghany, Doris B. Strader David L. Thomas and Leonard B. Seef. Diagnosis, management and treatment of Hepatitis C *Hepatology*, 2009; 49(4): 1336-1349.
- Masaki N, Fukushima S, Hayashi S. Lower Th-1/Th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. *Dig Dis Sci* 2002;47:2163-2169.
- Mast EE, Hwang LY, Seto DS, Notle FS, Nainan OV, Wurtzel H, Alter MJ. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J. Infect. Dis.* 2005; 192(11): 1880-1889.
  - Matloubian M, David A, Engel S, Ryan JE, Cyster JG. Transmembrane CXCL chemokine is a ligand for HIV-coreceptor. *Bonzo. Nat Immunol* 2000;1:298-304.
  - McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon study Group. *J Gastroenterol Hepatol* 2000; 15: 945-951.
- McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M L., Lee, W. M., Rustgi, V. K. et al. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *NEJ of Medicine* 339, 1485–92.

- Mele A, Corona R, Tosti ME, Palumbo F, Moiraghi A, Novaco F et al. Beauty treatment and risk of parenterally transmitted hepatitis result from the hepatitis surveillance system in Italy. *Scand J Infect Dis* 1995; 27: 441-44
- Metwally MA, Zein CO, Angulo P, Zein NN. A simple non-invasive scoring system for prediction of severe hepatic fibrosis in chronic hepatitis C patients. *Hepatology* 2001; 34: 230.
- Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. *J Med Virol.* 2003;70: 562-570.
- Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. *J Clin Invest* 1996; 98: 706-14.
- Mjor ME, Feinstone SM. The molecular virology of hepatitis C *Hepatology* 1997; 25: 1527-38.
- Mohamed MK, Abdel-Hamid M, Mikhail NN, Abdel-Aziz F, Medhat A, Magder LS, Fix AD, et al. Intrafamilial transmission of Hepatitis C in Egypt. *Hepatology* 2005; 42: 683-687.
- Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotypes. *Journal of Hepatology* 1999; 31: 65-70.
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br. J. Psychiatry* 1979; 134: 382-389.
- Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C et al. Viral and host factors in early hepatitis C virus infection. *Hepatology* 2005; 42(1): 86-92.

- Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 1989;7:145-173.
- Moreau, I., Levis, J., Crosbie, O., Kenny-Walsh, E., and Fanning, L.J. 2008. Correlation between pretreatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. *Virology* 5:78.
- Muhammad N, Jan MA. Frequency of hepatitis C in Buner, NWFP. *JCPSP*. 2005; 15(1): 11-14.
- Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E & Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. *Nature* 2001 410 50–56.
- Murphy PM, Baggiolini M, Charo IF, et al. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol Rev* 2000;52:145-76.
- Napoli J, Bishop GA, McGuinness PH, Painter DM, Caughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th-1 associated cytokines. *Hepatology* 1996; 24: 759-765.
- Niederaw C, Sannenborg A, Muller JE, Erckenbrecht JF, Scholten T, Fritsch WP. Sonographic measurements of normal liver, spleen, pancreas and portal vein. *Radiology* 1983; 149: 537-540.

- Ni J, Hembrador E, Di Bisceglie AM, et al. Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. *J Immunol.* 2003;170: 3429-3439.
- Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, Gallois Y, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. *Gastroenterology* 1997; 113: 1609-1616.
- Pan Y, Lloyd C, Zhou H, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. *Nature* 1997;387:611-7. [Erratum, *Nature* 1997; 389:100.]
- Pascal Perney, Chrystell Turriere, Pierre Portals, Helene Rigole, Christina Psomas, Francois Blane, Jacques clot, Pierre Corbeau. CXCR3 expression on peripheral CD4+ T-cells as a predictive marker of response to treatment in chronic hepatitis C. *Clinical Immunology* 2009; 132: 55-62.
- Pasha T, Gabriel S, Therneau T, Dickson ER and Lindor KD. Cost-effectiveness of ultrasound-Guided liver Biopsy. *Hepatology* 1998; 27: 1220-1226.
- Pawlotsky JM. Molecular diagnosis of viral hepatitis. *Gastroenterology* 2002; 122: 1554-1568.
- Pawlotsky JM, Pathophysiology of hepatitis C virus infection and related liver disease. *Trends Microbiol.* 2004; 12: 96-102.
- Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. *Hepatology* 2002; 36S.
- Pelkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B. 1-TAC/CXCL11 is a natural antagonist for CCRs. *J Leukoc Biol.* 2004; 76: 701-708.

- Persico, M., et al. 2008. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. *Gut*. 57:507–515.
- Philio L Shields, Clare M. Morland Michael Salmon, Shixin Qin, Stefan G. Hubscher and David H. Adams. Chemokine and chemokine receptor interactions provide a mechanism for selective T-cell recruitment to specific liver compartment within hepatitis C infected liver. *J. Immunol.* 1999; 163: 6236-43.
- Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C viral infection. *Am J Gastroenterol* 2001; 96: 3142-3146.
- Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. *J Virol.* 2001;75: 6095-6106
- Poynard, T., Marcellin, P., Lee, S. S., Niederaum, C., Minuk, G. S., Ideo, G. et al. (1998). Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *Lancet* 352, 1426–32.
- Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. *Lancet.* 2003;362: 2095-2100.
- Poznansky MC, Glszak IT. Evans RH et al. Thymocyte emigration is mediated by active movement away from stroma-derived factors. *J Clin Invest* 2002; 109: 1101-1110.
- Pradat P, Gaillat-VLLETe, Sahajian F, Bailly F, Excler G, Sepetjan M, Trepo C, et al. Prevalence of hepatitis C infection among general

- practice patients in Lyon area, France. *Eur. J. Epidemiol.* 2001; 17(1): 47-51.
- Pribila JT, Quale AC, Mueller KL, Shimizu Y. Integrins and T cell-mediated immunity. *Annu Rev Immunol* 2004; 22: 157-180
  - Proudfoot AEI, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. *Proc Natl Acad Sci U S A* 2003;100:1885-90.
  - Purcell RH. Hepatitis C virus. In: Webster RG, Granoff A, eds. *Encyclopedia of virology*. London, Academic Press Ltd, 1994; 569-74.
  - Pybus OG, Drummond AJ, Nakano T, Robertson BH, Rambaut A. The Epidemiology and Iatrogenic Transmission of hepatitis C virus in Egypt: A Bayesian Coalescent Approach. *Molecular Biology Evaluation* 2003; 20(3): 381-387.
  - Radloff L. The CES-D scale: a self-report depression scale for research in the general population. *J Applied Psychol. Measurement* 1997; 1: 385-401.
  - Radkowski M, Gallegos-orocz JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wikinson J, et al. Occult viral hepatitis, what is the significance *Hepatology* 2005; 41: 106-114.
  - Ramalho F. Hepatitis C virus infection and liver steatosis. *Antiviral Research* 2003; 60(2): 125-127.
  - Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in Middle East. *International Journal of Infecious disease* 2006; 10: 272-7.
  - Rao MR, Naficy AB, Darwish MA, Darwish NM, Schisterman E, Clemens JD, Edelman R. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt *BMC infectious disease* 2002; 2: 29.

- Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pylsopoulos NT, Feng ZZ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol*. 2002; 97(10): 2614-2618.
- Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. *Hepatology*. 1999;30: 787-793.
- Renou C, Muller P, Jouve E, Bertand JJ, Raoult A, Benderriter T, Halfon P. Relevance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus. *Am J Gastroenterol* 2001; 96: 1657-1659.
- Rieu V, Cohen P, Andre MH, Mouthon L, Godmer P, Jarrousse B, Lhote F, et al. Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. *Rheumatology* 2002; 41: 290-300.
- Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. *Trends Immunol* 2004;25:201-9.
- Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokines grammar for immune cells. *Annu Rev Immunol* 2004;22:891-928.
- Rotondi M, Rosati A, Buonamano A, Lasagni L, Lazzeri E, Pradella F, et al. High pretransplant serum levels of CXCL 10/ IP10 are related to increased risk of renal allograft failure. *Am J Transplant* 2004; 4: 1466-1474.
- . Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. *J Hepatol* 2001;35:307.

- Ruk R. Chemokines. *Sci World J* 2007; 7: 224-232
- Ruiz J, Sangro B, Cuende JI. Hepatitis B and C viral infections in patients with hepatocellular carcinoma. *Hepatology* 1992; 16: 637-641.
- Salazar-Mather TP, Hamilton TA, Biron CA. A chemokine –to-cytokine-to chemokine cascade critical in antiviral defense. *J Clin Invest.* 2000; 105: 985-993.
  - Samuel S. Lee\* and Ayman A. Abdo(2003) , Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?*Journal of Antimicrobial Chemotherapy* 51, 487–491, DOI: 10.1093/jac/dkg135 Advance Access publication 11 February 2003
- Sandeep Mukherjee. Hepatitis e Medicine world medical library 2007.
- Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, et al. Transient elastography: a new non invasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol.* 2003; 29(12): 1705-1713.
- Sarris AH, Broxmeyer HE, Wirthmueller U, Karasavvas N, Copper S et al. Human interferon-inducible protein 10: Expression & purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. *J. Exp. Med.* 1993; 178(3): 1127-1132.
- Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. *Semin liver Dis* 2001; 21: 351-372
- Seeff LB. Natural history of chronic hepatitis C-*Hepatology* 2002; 36(Suppl): S35-S46.
- Seef LB. Natural history of hepatitis C. *Hepatology* 1997; 26: 21S.
- Shakil AO, Conry-Cantilenu C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, et al. Volunteer blood donors with

- antibody to hepatitis C virus. Clinical, biochemical, virologic, and histologic features. *Ann Intern Med* 1995; 123: 330-337.
- Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokines and chemokine receptor interactions provide a mechanism for selective T-cell recruitment to specific liver compartments within hepatitis C-induced liver. *J Immunol.* 1999; 163: 6236-6243.
  - Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. *J Immunol.* 1999;163: 6236-6243.
  - Shimaoka T, Kume N, Minami M, et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. *J Biol Chem* 2000;275:40663-6.
  - Shirakawa, H., et al. 2008. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. *Hepatology*. Online publication ahead of print. doi:10.1002/hep.22543.
  - Shiratori, Y., Kato, N., Yokosuka, O., Imazeki, F., Hashimoto, E., Hayashi, N. et al. (1997). Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. *Gastroenterology* 113, 558–66.
  - Shobokshi O, Serebour E, Skakni L, Al Saffy Y, Ahdal M. Hepatitis genotypes and subtypes in Saudi Arabia. *J. Med. Virol.* 1999; 58: 44-48.
  - Simmonds P. Viral heterogeneity of the hepatitis C virus. *Journal of Hepatology* 1999; 31: 54-60.

- Sitia G, Isogawa M, Iannacone M, Campbell IL, Chisan-FV, Guidotti LG. MMPs are required for recruitment of antigen-non specific mononuclear cells into the liver by CTLs. *J Clin Invest.* 2004; 113:1158-1167.
- Siveke JT and A Hamann. T helper 1 and T helper 2 cells respond differentially to chemokines. *J Immunol.* 1998; 160: 550.
- Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration. The multistep paradigm. *Cell* 1994; 76: 301.
- Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RJ, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. *NEJ Med* 2004; 351(8): 760-768.
- Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NH, Esmat G, et al. Role of hepatitis C infection in chronic liver disease in Egypt. *Am. J. Trop. Med. Hyg.* 2002; 67: 436-42.
- Strickland GT. Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of Iatrogenic and Biological Factors. *Hepatology* 2006; 43: 915-922.
- Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. *Semin Cancer Biol* 2004;14: 195-200.
- Su AL, Pezacki JP, Wodicka L et al. Genomic analysis of the host response to hepatitis C virus infections. *Proc Natl Acad Sci USA.* 2002; 99: 15669-15674.

- Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. *Int J Med Sci* 2006; 3(2): 41-46.
- Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. *Nature* 1998;393:591-4.
- Tanaka J, Kumagai J, Katayamu K, Komiya Y, Mizui M, Yamanaka R, Suzuki K et al. Sex-and age specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485, 748 first-time blood donors during 1999-2000. *Intervirolgy*, 2004; 47(1): 32-40.
- Tanak YK, Kimata K, Adams DH and Eto S. Modulation of cytokine function by proteoglycans. Sophisticated modles for regulation of cellular response to cytokines. *Proc. Assoc. Phys.* 1998; 110: 118.
- Tang S. Seroepidemiological study in hepatitis C virus infection among blood donors from various regions in China. *Chin. J. Epidemiol.* 1993; 14: 271-4.
- Tannaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U and Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 $\beta$ . *Nature* 1993; 361: 79.
- Tanner MA, Berk LS, Felten DL, Blidy AD, Bit SL, Ruff DW. Substantial changes in gene expression level due to the storage temperature and storage duration of human whole blood. *Clin. Lab. Haematol.* 2002; 24: 337-341.
- Taub DDSM, Turcovski-Corrales, Key ML, Longo DL and Murphy WJ. Chemokines and T-lymphocyte activation. IB chemokines costimulate human T lymphocyte activation. *J. Immunol.* 1996; 156: 2095.
- Taub DD, Longo DL and Murphy WJ. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes

- the migration of human T-lymphocytes into the peripheral-tissues of human peripheral-blood lymphocytes-scid mice. *Blood* 1996; 87: 1423.
- Taylor DR, Shi ST, Romano PR, Brber GN, Lai MC. Inhibition of interferon-inducible protein kinase PKR by HCV E<sub>2</sub> protein. *Science* 1999; 285: 107-10.
  - Taylor MW, Grosse WM, Schaley JE et al. Global effect of PEG-IFN- $\alpha$  and ribavirin on gene expression in PBMC in vitro. *J Interferon cytokine Res.* 2004; 24: 107-118
  - Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. *Gastroenterology.* 2010;139(1):120–129.e11
  - Thomas DL, Seeff LB, Natural history of hepatitis C. *Clin Liver Dis* 2005; 9: 383-398.
  - Thomas S. Oh and Charles M. Rice Predicting response to hepatitis C therapy *The Journal of Clinical Investigation* Volume 119 Number 1 January 2009 5:7
  - Torres-Puente, M., et al. 2008. Genetic variability in hepatitis C virus and its role in antiviral treatment response. *J. Viral Hepat.* 15:188–1998.
  - Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, Coppola RC et al. Epidemiology of hepatitis C virus infection in seven European union countries: a critical analysis of the literature. HENCORE Group

(Hepatitis C European Network for cooperative Research). *Eur J Gastroenterol Hepatol.* 2000; 12: 667-78.

- Tsou C-L, Haskell CA, Charo IF. Tumor necrosis factor- $\alpha$ -converting enzyme mediates the inducible cleavage of fractalkine. *J Biol Chem* 2001;276:44622-6.
- Van der Poel CL, Hepatitis C virus blood transfusion: past and present risks. *Journal of Hepatology*, 1999; 31: 101-106.
- Van Damme P, Thyssen A, Van Loock F. Epidemiology of hepatitis C in Belgium: Present and future *Acta Gastroenterol BPLg.* 2002; 65: 78-79.
- Voisset C, Callens N, Blanchard E, De Beeck EO, Dubuisson J and Vudac N. High Density Lipoproteins facilitate Hepatitis C virus Entry through the scavenger receptors class B type I. *J. Biol. Chem.* 2005; 280(9): 7793-9.
- von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. *NE J Med.* 2000;343: 1020-1034.
- Walker CM. Hepatitis C virus. In: Ahmed R, Chen I, eds. *Persistent viral infections.* Chichester, Wiley, 1999; 93-115.
- Wang Y, Tao QM, Zhao HY, Tsuda F, Nagayama R, Yamamoto K, Tanaka T et al. Hepatitis C virus RNA and antibodies among blood donors in Beijing. *J. Hepatol* 1994; 21: 634-40.
- Wasley A, Miller JT, Finelli L, Surveillance for acute viral hepatitis- united states 2005 *MMWR Surveill Sum* 2007; 56: 1-24. Wasmuth HE, Werth A, Mueller T, et al. Heptotype-tagging RANTES gene variants

influence response to antiviral therapy in chronic hepatitis C.

Hepatology. 2004; 40: 327-334.

- Webster G, Whalley S, Barnes E et al. Hepatitis C and G. In: O'Grady J Howdle P. Comprehensive clinical hepatology 1<sup>st</sup> ed. Mosby 2000; 136-43.
- Wejstal R. Sexual transmission of hepatitis C virus. Journal of Hepatology, 1999; 31: 92-95.
- Weill FS. Ultrasonography of digestive disease – 1<sup>st</sup> ed. Saint Louis: The C.V. Mosby Company 1978.
- Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 2005; 39 (4 suppl 2): S158-161.
- Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-526.
- Woitas RP, Lechmann M, Junge G, Kaiser R, Sauerbuch T and Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T-lymphocytes J. Immunol. 1997; 159: 1012.
- Wong, D. K., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S. & Heathcote, J. (1993). Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Annals of Internal Medicine 119, 312–2
- Wong JB, Natural history of fibrosis in chronic hepatitis C Hepatology 2003; 38: 4.
- Wuttge DM, Zhou X, Sheikine Y, et al. CXCL16/SR-PSOX is an interferon- $\gamma$ -regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004;24:750-5.

- Yamada E, Montoya M, Schuettler CG, Hickling TP, Tarr AW, Vitelli A, Dubuisson J et al. Analysis of the binding of hepatitis C virus genotype 1a and 1b E<sub>2</sub> glycoproteins to peripheral blood mononuclear cell subsets J Gen Virol 2005; 86: 2507-12.
- Zanetti AR, Tanzi E, Newell ML. Mother-to-infant transmission of hepatitis C virus. Journal of Hepatology 1999; 31: 96-100.
- Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M. Y., Gane, E. et al. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C. NEJ Medicine 343, 1666–72.
- Zeuzem S, Welsch C, Herrmann E, Pharmacokinetics of peginterferons. Semin. Liver Dis 2003; (Suppl 1): 23-28.
- Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-9.
- Zung WW. A self-Rating Depression Scale. Arch Gen Psychiatry 1965; 16: 63-70.